149 related articles for article (PubMed ID: 34031528)
1. A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells.
Park M; Hwang JW; Cho Y; Kim S; Han SH; Yu J; Ha S; Kim WY; Kim SN; Kim IS; Kim YK
Sci Rep; 2021 May; 11(1):10822. PubMed ID: 34031528
[TBL] [Abstract][Full Text] [Related]
2. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
3. YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells.
Gao M; Liu T; Li J; Guan Q; Wang H; Yan S; Li Z; Zuo D; Zhang W; Wu Y
Toxicol In Vitro; 2020 Dec; 69():104971. PubMed ID: 32805372
[TBL] [Abstract][Full Text] [Related]
4. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
5. 4'-methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic agent.
Marinho J; Pedro M; Pinto DC; Silva AM; Cavaleiro JA; Sunkel CE; Nascimento MS
Biochem Pharmacol; 2008 Feb; 75(4):826-35. PubMed ID: 18036572
[TBL] [Abstract][Full Text] [Related]
6. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
7. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation.
Li S; Zhao Q; Wang B; Yuan S; Wang X; Li K
Phytother Res; 2018 Aug; 32(8):1530-1536. PubMed ID: 29635751
[TBL] [Abstract][Full Text] [Related]
8. TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization.
Jia L; Gao X; Fang Y; Zhang H; Wang L; Tang X; Yang J; Wu C
Apoptosis; 2022 Dec; 27(11-12):1015-1030. PubMed ID: 36107354
[TBL] [Abstract][Full Text] [Related]
9. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
10. 5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents.
Shahraki O; Khoshneviszadeh M; Dehghani M; Mohabbati M; Tavakkoli M; Saso L; Edraki N; Firuzi O
Molecules; 2020 Apr; 25(8):. PubMed ID: 32316291
[TBL] [Abstract][Full Text] [Related]
11. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
12. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
[TBL] [Abstract][Full Text] [Related]
13. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
14. A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport.
Zang X; Wang G; Cai Q; Zheng X; Zhang J; Chen Q; Wu B; Zhu X; Hao H; Zhou F
Drug Metab Dispos; 2018 May; 46(5):542-551. PubMed ID: 29523600
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
16. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional tissue culture model of human breast cancer for the evaluation of multidrug resistance.
Ding Y; Liu W; Yu W; Lu S; Liu M; Kaplan DL; Wang X
J Tissue Eng Regen Med; 2018 Sep; 12(9):1959-1971. PubMed ID: 30055109
[TBL] [Abstract][Full Text] [Related]
18. A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway.
Chiang NJ; Lin CI; Liou JP; Kuo CC; Chang CY; Chen LT; Chang JY
PLoS One; 2013; 8(3):e58953. PubMed ID: 23554962
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
20. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
